Wegovy vs. Qsymia
Wegovy and Qsymia differ fundamentally in mechanism and purpose. Wegovy is a GLP-1 receptor agonist, while Qsymia combines phentermine and topiramate for chronic weight management. Both achieve significant weight loss, though Wegovy reports an average of 15% of bodyweight, while Qsymia's reports an average of 6.6% to 8.6%. Both share common side effects, including nausea, but Qsymia may present additional risks related to its stimulant component. Wegovy costs $1,375/month, far exceeding Qsymia’s $300/month. Neither currently faces shortages.
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and fatigue.
Serious Potential Side Effects
Pancreatitis, gallbladder issues, kidney problems, and increased heart rate, thyroid cancer, anaphylaxis (or serious allergic reactions)
Phentermine suppresses appetite by stimulating the release of norepinephrine in the brain; topiramate enhances feelings of fullness and alters taste perceptions, reducing food intake.
Common Side Effects
Dry mouth, insomnia, constipation, dizziness, and tingling in hands or feet.
Serious Potential Side Effects
Increased heart rate, mood changes, suicidal thoughts, and memory/concentration difficulties, dependency and abuse of medication